Follow us for updates
© 2022
Read the Story →

COVID-19 Pills Now Available at VP Leni Robredo's Office

Molnupiravir will be administered with the guidance of QualiMed.
by Clara Rosales
Nov 23, 2021
Photo/s: Office of the Vice President

Vice President Leni Robredo on Monday said Molnupiravir, an oral pill used as COVID-19 treatment, is now available at her office for qualified patients.

A memorandum of agreement was signed with QualiMed Health Network to provide assistance for referred patients prescribed with Molnupiravir under the Bayanihan E-Konsulta Program.

"The [Office of the Vice President] will issue a guarantee letter under our special medical assistance program to any qualified patient referred by our volunteer doctors at Bayanihan E-Konsulta. QualiMed facilties will then further assess and prescribe the medicine to the patient," the statement said.

Molnupiravir, manufactured by U.S. pharmaceutical company Merck, is used for mild to moderate cases of COVID-19, and was shown to reduce hospitalization for newly infected patients by 50%. Philippines received its shipment on Nov. 17, the first in Southeast Asia.

Continue reading below ↓


COVID Treatments: What Works, What Doesn't, What Might

WHO is Mass-Testing Three Potential COVID Treatments

Continue reading below ↓
Recommended Videos

Reportr is now on Quento. Download the app or visit the Quento website for more articles and videos from Reportr and your favorite websites.

Latest Headlines
Read Next
Recent News
Some relief from rising prices.
With the reopening of several local destinations, this app has never been more timely.
Landmark Roe vs Wade ruling of 1973 is overturned.
Its rise mirrors the rise of technology for the masses.
It cites global uncertainties for its move.
The news. So what? Subscribe to the newsletter that explains what the news means for you.
The email address you entered is invalid.
Thank you for signing up to On Three, reportr's weekly newsletter delivered to your mailbox three times a week. Only the latest, most useful and most insightful reads.
By signing up to newsletter, you agree to our Terms of Service and Privacy Policy.